Saturday, July 11, 2026

pharma · Acute Ischemic Stroke

Beijing Tiantan Hospital

Beijing Tiantan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Acute Ischemic Stroke. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s)

Beijing, CN HQ
124 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Beijing, CN
Employees
124
Programs
1
Drugs
2
Patents
0

Quick answer

Beijing Tiantan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Acute Ischemic Stroke. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1).

Company snapshot

Beijing Tiantan Hospital is a company based out of Beijing, China.

  • 1 active pipeline program(s) linked via ClinicalTrials.gov.
  • 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Beijing Tiantan Hospital. Not investment advice.

Lead pipeline drugs

  • Marketed / approved
  • Marketed / approved
  • rt-pa Acute Ischemic Stroke
    Phase 3

Active clinical programs

  • rt-PA Acute Ischemic Stroke
    Phase 3
Momentum signals

Momentum

Proprietary activity score for Beijing Tiantan Hospital.

1 active signal

7 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 1 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d
Competitive landscape
Recent activity

Recent activity

Latest pipeline, patent, and corporate events for Beijing Tiantan Hospital.

  1. Clinical update

    rt-PA — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Beijing Tiantan Hospital?

    Beijing Tiantan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Acute Ischemic Stroke. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and

  • Is Beijing Tiantan Hospital publicly traded?

    Beijing Tiantan Hospital appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Beijing Tiantan Hospital develop or market?

    We link 2 drug profile(s) where Beijing Tiantan Hospital is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/beijing-tiantan-hospital#company-drugs.

  • What are the latest developments for Beijing Tiantan Hospital?

    In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Beijing Tiantan Hospital focus on?

    Beijing Tiantan Hospital focuses on Acute Ischemic Stroke based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
2